Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of YouTube as an Information Platform for Ovarian Cancer: the Educational Quality and Reliability.

Yonsei medical journal·2026
Same author

Factors affecting health-related quality of life in cervical cancer survivors: a multicenter cross-sectional study in Korea.

BMC women's health·2026
Same author

<i>In Silico</i> Investigation of Amidine-Based BACE-1 Inhibitors Against Alzheimer's Disease: SAR, Pharmacokinetics, Molecular Docking and Dynamic Simulations.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Risk Factors of High-Grade CIN or Cervix Cancer in Young Women with Abnormal Pap Smear Results: Who Should Be Treated with LEEP (Loop Electrosurgical Excision Procedure)?

Journal of clinical medicine·2025
Same author

Focal adhesion kinase plays an essential role in Th17 cell differentiation by stimulating NF-κB signaling.

Frontiers in immunology·2025
Same author

Toxic Effects of Waterborne Nitrite on LC<sub>50</sub>, Hematological Parameters, and Plasma Biochemistry in Starry Flounder (<i>Platichthys stellatus</i>).

Toxics·2025

Related Experiment Video

Updated: Jan 16, 2026

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

15.6K

A Tissue Factor Bi-Specific T-Cell Engager Provides Effective Targeting and Cytotoxicity Against Cervical Cancer Cell

Kyung-Jun Lee1, Gilhyang Kim2,3, Booseong Seo4

  • 1Institute of New Frontier Research Team, Hallym University, Chuncheon 24252, Republic of Korea.

International Journal of Molecular Sciences
|September 27, 2025
PubMed
Summary

A novel bi-specific T-cell engager (BiTE) targeting Tissue Factor (TF) demonstrates potent cytotoxicity against cervical cancer cells. This TF-BiTE therapy effectively activates T cells, showing promise for cervical cancer immunotherapy.

Keywords:
bispecific T-cell engagercervical cancerimmunotherapytargeted therapytissue factor

More Related Videos

Use of Interferon-&#947; Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.9K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K

Related Experiment Videos

Last Updated: Jan 16, 2026

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

15.6K
Use of Interferon-&#947; Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.9K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Tissue Factor (TF), a transmembrane glycoprotein, is highly expressed in various cancers, correlating with poor prognosis.
  • TF's role in cancer progression necessitates novel therapeutic strategies for improved patient outcomes.

Purpose of the Study:

  • To evaluate the cytotoxicity of a novel bi-specific T-cell engager (BiTE) targeting Tissue Factor (TF) in cervical cancer cell lines.
  • To characterize the T-cell activation and mediated cytotoxicity induced by the TF-BiTE.

Main Methods:

  • Design and characterization of a humanized BiTE utilizing anti-CD3 and anti-TF single-chain variable fragments (scFvs).
  • Assessment of TF-BiTE potency and replication in cervical cancer cell lines (SiHa, ME-180, HeLa).
  • Evaluation of T-cell activation, proliferation, degranulation, and cytokine release via flow cytometry in vitro.

Main Results:

  • TF expression was confirmed in SiHa, ME-180, and HeLa cervical cancer cell lines.
  • The TF-BiTE exhibited potent TF-specific cytotoxicity and effectively induced T-cell activation, proliferation, degranulation, and cytokine release.
  • These therapeutic effects were specific to TF-expressing cells, with no observed effects in TF-negative controls.

Conclusions:

  • The developed TF-BiTE demonstrates significant anti-cancer activity against cervical cancer cells.
  • TF-BiTE therapy holds promise as a potential immunotherapeutic agent for cervical cancer treatment.
  • Further investigation into TF-BiTE as a therapeutic candidate for cervical cancer immunotherapy is warranted.